CIViC Compass
Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.

CIViC Evidence Items

4766 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline
BClinical — prospective trial or retrospective cohort study
CCase study — single case report or small case series
DPreclinical — in vitro or animal model data
EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

PredictiveDiagnosticPrognosticFunctionalPredispos.Oncogenic
BCR::ABL132311
BRAF18642621
EGFR2481232
EML4::ALK64
ERBB21422
FLT355221
KIT10237
KRAS1594244
PIK3CA156164
PTEN5313121
TP5352401002
VHL52363515
Predictive:Links a variant to treatment response or resistance
Diagnostic:Supports or refutes a specific disease diagnosis
Prognostic:Informs disease progression or clinical outcome
Functional:Characterises the biological effect of a variant
Predisposing:Germline variant associated with cancer predisposition
Oncogenic:Characterises the variant's role in oncogenesis
LevelGeneVariantTypeDirectionSignificanceDiseaseDrugsSource
DKITL576PPredictiveSupportsSensitivity/ResponseCancerDasatinib,ImatinibVita et al., 2014
CKITD579delPredictiveSupportsResistanceGastrointestinal Stromal TumorSunitinibHeinrich et al., 2008
BKITWildtypePredictiveSupportsSensitivity/ResponseGastrointestinal Stromal TumorRegorafenib AnhydrousBen-Ami et al., 2016
CEGFRE746_T751>IPredictiveSupportsSensitivity/ResponseLung AdenocarcinomaGefitinibPao et al., 2004
CEGFRL747PPredictiveDoes Not SupportSensitivity/ResponseLung Non-small Cell CarcinomaGefitinib,ErlotinibWu et al., 2011
CEGFRV774MPredictiveDoes Not SupportSensitivity/ResponseLung Non-small Cell CarcinomaErlotinibWu et al., 2011
CEGFRK806EPredictiveDoes Not SupportSensitivity/ResponseLung Non-small Cell CarcinomaGefitinibWu et al., 2011
CEGFRN826YPredictiveDoes Not SupportSensitivity/ResponseLung Non-small Cell CarcinomaGefitinibWu et al., 2011
CEGFRN842SPredictiveDoes Not SupportSensitivity/ResponseLung Non-small Cell CarcinomaGefitinibWu et al., 2011
CEGFRT847IPredictiveDoes Not SupportSensitivity/ResponseLung Non-small Cell CarcinomaGefitinibWu et al., 2011
CEGFRV851IPredictiveDoes Not SupportSensitivity/ResponseLung Non-small Cell CarcinomaGefitinibWu et al., 2011
DEGFRL838VPredictiveSupportsResistanceCancerGefitinib,ErlotinibKancha et al., 2009
DEGFRL858RPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaErlotinibLi et al., 2008
DEGFRL858RPredictiveSupportsSensitivity/ResponseCancerErlotinibHarada et al., 2011
BEGFRL858RPredictiveSupportsSensitivity/ResponseLung AdenocarcinomaErlotinibDe Grève et al., 2016
DEGFRL858RPredictiveSupportsSensitivity/ResponseLung AdenocarcinomaErlotinibKonduri et al., 2016
DEGFRL858RPredictiveSupportsSensitivity/ResponseLung Small Cell CarcinomaErlotinibCross et al., 2014
DEGFRL858RPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaOsimertinibCross et al., 2014
CBCR::ABL1Fusion AND ABL1 M244VPredictiveDoes Not SupportResistanceChronic Myeloid LeukemiaDasatinibTalpaz et al., 2006
CBCR::ABL1Fusion AND ABL1 M244VPredictiveDoes Not SupportResistanceChronic Myeloid LeukemiaBosutinibCortes et al., 2011
CBCR::ABL1Fusion AND ABL1 M244VPredictiveDoes Not SupportResistanceChronic Myeloid LeukemiaBosutinibKhoury et al., 2012
CBCR::ABL1Fusion AND ABL1 L248VPredictiveDoes Not SupportResistanceChronic Myeloid LeukemiaBosutinibCortes et al., 2011
DBCR::ABL1Fusion AND ABL1 L248VPredictiveSupportsResistanceChronic Myeloid LeukemiaAxitinibPemovska et al., 2015
CBCR::ABL1Fusion AND ABL1 G250EPredictiveDoes Not SupportResistanceChronic Myeloid LeukemiaBosutinibCortes et al., 2011
CBCR::ABL1Fusion AND ABL1 G250EPredictiveSupportsReduced SensitivityChronic Myeloid LeukemiaBosutinibKhoury et al., 2012
DBCR::ABL1Fusion AND ABL1 G250EPredictiveSupportsResistanceChronic Myeloid LeukemiaAxitinibPemovska et al., 2015
DBCR::ABL1Fusion AND ABL1 G250EPredictiveSupportsResistanceChronic Myeloid LeukemiaAxitinibZabriskie et al., 2016
DBCR::ABL1Fusion AND ABL1 Q252HPredictiveSupportsResistanceChronic Myeloid LeukemiaAxitinibPemovska et al., 2015
DBCR::ABL1Fusion AND ABL1 Q252HPredictiveSupportsResistanceChronic Myeloid LeukemiaAxitinibZabriskie et al., 2016
DBCR::ABL1Fusion AND ABL1 Y253HPredictiveDoes Not SupportResistanceChronic Myeloid LeukemiaAxitinibPemovska et al., 2015
DBCR::ABL1Fusion AND ABL1 Y253HPredictiveSupportsResistanceChronic Myeloid LeukemiaAxitinibZabriskie et al., 2016
CBCR::ABL1Fusion AND ABL1 Y253HPredictiveDoes Not SupportResistanceChronic Myeloid LeukemiaBosutinibCortes et al., 2011
DBCR::ABL1Fusion AND ABL1 Y253FPredictiveSupportsResistanceChronic Myeloid LeukemiaAxitinibPemovska et al., 2015
DBCR::ABL1Fusion AND ABL1 E255KPredictiveSupportsResistanceChronic Myeloid LeukemiaAxitinibPemovska et al., 2015
DBCR::ABL1Fusion AND ABL1 D276GPredictiveSupportsResistanceChronic Myeloid LeukemiaAxitinibPemovska et al., 2015
CBCR::ABL1Fusion AND ABL1 T315IPredictiveSupportsResistanceChronic Myeloid LeukemiaBosutinibKhoury et al., 2012
CBCR::ABL1Fusion AND ABL1 T315IPredictiveSupportsResistanceChronic Myeloid LeukemiaBosutinibCortes et al., 2011
CBCR::ABL1Fusion AND ABL1 T315IPredictiveSupportsResistanceChronic Myeloid LeukemiaDasatinibSoverini et al., 2016
DBCR::ABL1Fusion AND ABL1 T315IPredictiveSupportsSensitivity/ResponseChronic Myeloid LeukemiaAxitinibZabriskie et al., 2016
CBCR::ABL1Fusion AND ABL1 T315IPredictiveSupportsResistanceAcute Lymphoblastic LeukemiaDasatinibGuilhot et al., 2007
CBCR::ABL1Fusion AND ( ABL1 F317L OR ABL1 F317V )PredictiveSupportsResistanceChronic Myeloid LeukemiaDasatinibSoverini et al., 2016
DBCR::ABL1Fusion AND ABL1 F317LPredictiveSupportsResistanceChronic Myeloid LeukemiaAxitinibPemovska et al., 2015
DBCR::ABL1Fusion AND ABL1 F317LPredictiveSupportsResistanceChronic Myeloid LeukemiaAxitinibZabriskie et al., 2016
DBCR::ABL1Fusion AND ABL1 M351TPredictiveSupportsResistanceChronic Myeloid LeukemiaAxitinibZabriskie et al., 2016
BBCR::ABL1Fusion AND ABL1 E355GPredictiveDoes Not SupportResistanceChronic Myeloid LeukemiaDasatinibMüller et al., 2009
DBCR::ABL1Fusion AND ABL1 H396RPredictiveSupportsResistanceChronic Myeloid LeukemiaAxitinibPemovska et al., 2015
DBCR::ABL1Fusion AND ABL1 F486SPredictiveDoes Not SupportResistanceChronic Myeloid LeukemiaAxitinibPemovska et al., 2015
DBCR::ABL1Fusion AND ABL1 E255VPredictiveSupportsResistanceChronic Myeloid LeukemiaAxitinibPemovska et al., 2015
DBCR::ABL1Fusion AND ABL1 E255VPredictiveSupportsResistanceChronic Myeloid LeukemiaAxitinibZabriskie et al., 2016
CBCR::ABL1Fusion AND ABL1 E255VPredictiveDoes Not SupportResistanceChronic Myeloid LeukemiaBosutinibCortes et al., 2011
Page 77 of 96
PreviousNext